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Abstract 
Background: There is currently no clinical imaging technique available to assess the degree of inflammation associ-
ated with atherosclerotic plaques. This study aims to develop targeted superparamagnetic particles of iron oxide 
(SPIO) as a magnetic resonance imaging (MRI) probe for detecting inflamed endothelial cells.
Methods: The in vitro study consists of the characterisation and detection of inflammatory markers on activated 
endothelial cells by immunocytochemistry and MRI using biotinylated anti-P-selectin and anti-VCAM-1 (vascular cell 
adhesion molecule 1) antibody and streptavidin conjugated SPIO.
Results: Established an in vitro cellular model of endothelial inflammation induced with TNF-α (tumor necrosis fac-
tor alpha). Inflammation of endothelial cells was confirmed with both immunocytochemistry and MRI. These results 
revealed both a temporal and dose dependent expression of the inflammatory markers, P-selectin and VCAM-1, on 
exposure to TNF-α.
Conclusion: This study has demonstrated the development of an in vitro model to characterise and detect inflamed 
endothelial cells by immunocytochemistry and MRI. This will allow the future development of contrast agents and 
protocols for imaging vascular inflammation in atherosclerosis. This work may form the basis for a translational study 
to provide clinicians with a novel tool for the in vivo assessment of atherosclerosis.
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Background
Atherosclerosis is a dynamic, progressive disease arising 
from the combination of endothelial dysfunction with a 
compensatory inflammatory response [1]. Inflammation 
is not only instrumental in the development of atheroma-
tous plaques, but is also a key driver of plaque instability 
subsequently developing clinically significant symptoms 
such as stroke and myocardial infarction [1].
Current clinical techniques for imaging atherosclerotic 
disease include angiography, magnetic resonance angi-
ography (MRA), computed tomography angiography 
(CTA) or ultrasound which principally gives an accurate 
assessment of degree of luminal stenosis caused by 
atheroma. However, none of these techniques offer 
insight about the biological behaviour of atheromatous 
plaques—particularly degree of inflammation—which 
cause significant clinical events such as plaque instability 
and rupture [2].
MRI (magnetic resonance imaging) has advantages 
over other imaging modalities in clinical use, as it is non-
invasive, does not involve ionising radiation and is able 
to provide high resolution images of the vessel wall at a 
sub-millimetre level [3]. In addition, recent development 
of advanced MR contrast agents that selectively target 
molecules involved in plaque inflammation, offering the 
promise of in vivo molecular MR imaging of atheroscle-
rosis [4] and ex  vivo MR imaging of vulnerable carotid 
plaque [5].
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By exploiting specific ‘inducible’ molecular targets, 
or cellular events in diseases, molecular imaging uses 
targeted imaging agents to generate the image con-
trast [6]. One of the earliest events in atherosclerosis is 
the over-expression of adhesion molecules on the acti-
vated endothelium following exposure to inflammatory 
cytokines [7]. These pathophysiologically ‘inducible’ 
endothelial adhesion molecules, such as VCAM-1 (vas-
cular cell adhesion molecule-1) and P-selectin, have the 
potential to serve as attractive biomarkers for imaging 
inflammation in atherosclerosis. VCAM-1 (CD106) is 
an immunoglobulin superfamily glycoprotein (100–
110  kDa) expressed on activated endothelial cells, mac-
rophages and smooth muscle cells [8]. It has a vital role in 
monocyte recruitment in early stages of atherosclerosis 
[9]. Its expression is upregulated by activated endothe-
lium under inflammation, unlike resting endothelial cells 
[8]. The increased level of expression appears to be cor-
related with the extent of exposure to the atherosclerotic 
risk factors [8]. P-selectin (CD62P, GMP-140, PADGEM), 
a single-chain glycoprotein, is an adhesion molecule 
expressed on the surface of activated endothelial cells, 
which line the luminal surface of blood vessels, and on 
activated platelets [10]. It mediates initial leukocyte roll-
ing, preceding leukocyte diapedesis into the atheroscle-
rotic lesions [10, 11]. Similar to VCAM-1, P-selectin is 
rapidly mobilized to the surface of endothelial cells and 
platelets in response to stimuli [10]. These features ren-
der VCAM-1 and P-selectin an ideal biomarker for func-
tional molecular imaging and targeted therapeutics in 
early atherosclerosis.
To achieve targeted molecular MR imaging, smarter 
contrast agents are required to identify the molecules of 
interest (i.e. endothelial adhesion molecules in athero-
sclerosis) with high specificity. Specificity can be achieved 
through conjugation of contrast agents with monoclonal 
antibodies, or their immunospecific fragments F(ab) or 
peptides. Recent advances in this area include oxidized 
low-density lipoprotein (oxLDL)-targeted iron oxide 
nanoparticles [12] and scavenger receptor-AI-targeted 
iron oxide nanoparticles [13].
SPIO (superparamagnetic particles of iron oxide) nan-
oparticles are composed of an iron oxide core coated 
with a biocompatible polymer with size ranging from 
50–300  nm. Various iron-oxide nanoparticle prepara-
tions are under clinical trials and their safety profile has 
been increasingly recognised [14]. Iron-oxide particles 
have become the favoured contrast agent for a num-
ber of reasons. Firstly, they have a known biocompat-
ibility profile with their degradation occurring through 
normal physiologic iron metabolism pathways [15]. By 
contrast, gadolinium chelates, the clinically used MRI 
contrast agent, has been reported to have potential severe 
long-term toxicity effects, including nephrogenic scleros-
ing fibrosis in patients with impaired renal function [16]. 
Secondly, iron-oxide particles have high sensitivity due 
to iron-oxide’s inherent superparamagnetism. They dis-
tort magnetic fields, creating marked contrast effects far 
exceeding their physical size, thereby strongly enhancing 
the transverse relaxation times T2 and T2*. Hence, they 
act as contrast agents for T2 sequence [15]. T2 technique 
is a relaxation time measurement contributing to the 
transverse decay of the MR signal that arise from natural 
interactions at the atomic and molecular levels within the 
tissue or substance of interest. T2* can be considered an 
“observed” T2, whereas T2 can be considered the “true” 
T2 of the tissue being imaged [17].
Iron-oxide nanoparticles have the potential to open 
up new avenues into molecular MR imaging, in both 
pre-clinical and clinical studies. Indirect quantitative 
methods utilising the non-specific uptake of iron-oxide 
particles by macrophages to identify plaque inflamma-
tion, have been reported [18]. The present study is an 
exploratory qualitative study aimed at visualising and 
characterising atherosclerosis using targeted SPIO as an 
MRI probe for detecting inflamed endothelial cells. It is 
hypothesized that highly specific antibody-conjugated 
SPIO would enable MRI of inflamed endothelial cells.
Methods
Induction of inflammation on endothelial cells by TNF‑α
Mouse aortic endothelial cells (mAEC) (Innoprot, Spain) 
were cultured in an endothelial cell medium consist-
ing of Dulbecco’s Modified Eagle Medium containing 
4500  mg/L glucose, l-glutamine and pyruvate, supple-
mented with 25 μg/mL of gentamicin, 2 mM glutamine, 
5% of fetal calf serum, 1  μg/mL of hydrocortisone, 10 
units of heparin, 10  ng/mL of recombinant human epi-
dermal growth factor (PeproTech Ltd, London, UK) and 
3 ng/mL of recombinant human fibroblast growth factor 
(PeproTech Ltd, London, UK). mAEC were subsequently 
incubated with 0.1, 1, 10 and 100  ng/mL recombinant 
mouse TNF-α (Sigma, MO, USA) for 4, 24 and 48  h at 
37  °C to induce endothelial VCAM-1 and P-selectin 
expression. mAECs without exposure to TNF-α served as 
controls.
Detection of inflammatory markers on mAEC 
by immunocytochemistry
mAECs on coverslips were harvested and fixed with 
4% paraformaldehyde (PFA) for 15  min, permeabilized 
with 0.1% Triton X-100 for 5  min and blocked with 5% 
bovine serum albumin (BSA) for 30 min. Cells were then 
incubated with biotinylated primary antibody against 
VCAM-1 (Vector Laboratories, Burlingame, USA) and 
P-selectin (Vector Laboratories, Burlingame, USA) at 
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room temperature for 1 h, followed by streptavidin anti-
bodies (Alexa Fluor® 594 streptavidin, Thermofisher 
Scientific, Inc.) for 30  min at room temperature. After 
repeated wash with PBS, coverslips were mounted on a 
slide in antifade reagent with DAPI (ThermoFisher Scien-
tific Inc.). An Olympus IX-83 inverted microscope fitted 
with a 60×, 1.4 NA oil immersion objective (Olympus), 
and a monochrome CCD camera (Olympus) driven using 
CellSens (Olympus) were used. VCAM-1 and P-selectin 
fluorescence intensity per cell were quantified using soft-
ware ImageJ [19, 20]
Corrected total cell fluorescence (CTCF)
= Integrated Density− (Area of selected cell×Mean fluorescence of background readings)
used as targeted ‘contrast agents’ for activated endothe-
lial cells, thereby making these cells ‘MR visible’. The cells 
were then incubated with the beads at 4  °C for 15  min 
and washed to remove unbound streptavidin microbeads 
afterwards. The cells were finally re-suspended in 150 μL 
of PBS and 150 μL of 2% agarose for cell phantom MRI. 
Inactivated cells (without TNF-α exposure) and activated 
cells incubated with biotinylated anti-mouse IgG (Vector 
Laboratories, Burlingame, USA) served as controls.
The cell suspensions in the tubes were embedded in 
2% agarose block (Sigma®, UK, Fig. 2). The cell phantom 
Fig. 1 Detection and characterisation of P-selectin and VCAM-1 on 
activated endothelial cells by antibody-conjugated SPIO
Detection of inflammatory markers on mAEC by MRI
mAECs on the culture plates were used for the SPIO tar-
geting to biotinylated antibodies conjugated on the cell 
surface as illustrated in Fig.  1. Firstly, the activated cells 
(1, 10 and 100  ng/mL TNF-α, 4  h) were washed twice 
by centrifugation (5000 rpm for 5 min) and incubated at 
room temperature for 20 min with the biotinylated anti-
P-Selectin and anti-VCAM-1 at a concentration of 10 μg/
mL diluted in 10% rabbit serum for labelling 107 cells. Fol-
lowing incubation, the cells were washed twice to remove 
unbound biotinylated antibodies with 2  mL of labelling 
buffer composed of PBS (1×), supplemented with 2 mM 
EDTA, and centrifuged. The buffer was kept at 4  °C 
throughout the experiment to prevent capping of antibod-
ies on the cell surface and non-specific cell labelling. The 
endothelial cell pellet was re-suspended in 90 μL of label-
ling buffer per 107 cells and 10 μL of streptavidin microbe-
ads (Miltenyi Biotec Ltd, Surrey, UK) per 107 cells. These 
streptavidin microbeads are iron-oxide beads (SPIO of 
50  nm diameter) conjugated to streptavidin and can be 
MRI was performed using a three tesla clinical whole 
body scanner (Achieva TX, Philips Healthcare, Best 
Netherlands). The samples were placed in a receive-only 
eight-channel SENSE wrist coil for optimal signal recep-
tion. A T2-weighted sequence (TR 2000 ms; TE 120 ms; 
number of slices 10; slice thickness 1 mm; FOV 80 mm; 
signal averages 30; matrix 266 ×  336) was employed in 
the transverse plane to obtain sectional images of the 
samples. The MR images were analysed using ImageJ 
software. The signal to noise ratio for each sample was 
calculated to allow comparison amongst the samples.
Statistical analysis
The findings were analysed using the statistical software 
GraphPad Prism 5. The intensity of staining (CTCF) 
and signal to noise ratio was quantified as mean ± SEM. 
Unpaired t test was used to compare the means of CTCF 
between different concentrations of TNF-α in each time 
point. One way analysis of variance (ANOVA) test was 
used to perform multiple comparisons of mean CTCF at 
different concentrations of TNF-α and incubation peri-
ods. P values less than 0.05 were taken as being statisti-
cally significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Results
Increased levels of P‑selectin and VCAM‑1 in activated 
mAEC
P-selectin and VCAM-1 were only detected in activated 
mAEC as shown by the red fluorescence signal at various 
concentrations of TNF-α and incubation periods, whilst 
no expression was observed in the untreated control cells 
(Figs. 3a, 4a). The dose response of TNF-α in mAEC was 
similar as detected by P-selectin and VCAM-1. Higher 
TNF-α concentration gave higher expression levels of 
both inflammatory markers, although the expression level 
was more obvious in VCAM-1 compared to P-selectin 
(Figs. 3b, 4b). In addition, VCAM-1 expression increased 
with time, with maximal signal at 48  h (Fig.  4b), while 
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P-selectin level was maximal at 4 h post-TNF-α stimula-
tion and then declined at 24 and 48 h (Fig. 3b).
MRI signal concurs with the degree of inflammation 
in mAEC
The transaxial view of cell phantom MRI is illustrated 
in Fig.  5a. The streptavidin microbeads control were 
detected as signal void in T2 sequence by MRI and 
hence, appeared to be darkest. The activated mAEC 
stimulated by higher concentration of TNF-α were 
observed to produce greater signal void, and appeared 
darker on the MR image. The mAEC stimulated by 
100  ng/mL TNF-α were observed to be the darkest 
amongst the three concentrations used, followed by 
10  ng/mL, and finally the least with 1  ng/mL TNF-α. 
In contrast, the negative controls: (1) PBS (2) untreated 
mAEC, and (3) activated mAEC added with bioti-
nylated IgG antibodies and microbeads were observed 
to produce minimal signal void, and appeared to be 
bright on the MR image.
In order to quantify these observations, the mean of the 
signal to noise ratio (S/N) in each sample in 5 consecutive 
MRI slices was measured. The results were illustrated in 
Fig. 5b. The S/N in microbeads control was 0.243, the low-
est amongst all the samples. This was consistent with the 
observation that the microbeads control appeared to be 
the darkest amongst all samples. The activated cells stimu-




P-selectin is an adhesion molecule expressed on the lumi-
nal surface of vascular endothelial cells under inflamma-
tion [10]. It is not expressed by resting endothelial cells, 
but can be induced in vitro and in vivo following stimu-
lation by pro-inflammatory mediators such as TNF-α or 
bacterial lipopolysaccharides [21, 22]. Previous studies 
have demonstrated P-selectin up-regulation in chronic 
inflammatory conditions such as rheumatoid arthritis [23] 
and inflammatory bowel disease [24]. By using P-selectin 
conjugated USPIO, Jacobin–Valat et  al. demonstrated 
the expression of P-selectin on human activated platelets 
involved in the early stages of atherosclerosis [11]. Con-
sistent with these studies, we confirmed that P-selectin 
expression was detected only on the activated mAECs, 
but not on the quiescent control mAEC (Fig. 3).
In our study, the P-selectin expression on activated 
mAEC was maximal at 4 h post-TNF-α stimulation, but 
declined after 24 and 48 h. Similar transient expression of 
P-selectin in vitro has been reported on murine endothe-
lial cells with maximal expression at 3  h after stimula-
tion with TNF-α [21]. We have also demonstrated that 
the level of P-selectin expression was dose-dependent on 
exposure to TNF-α, which is similar to E-selectin [25].
The role of VCAM-1 in the inflammatory initiation of 
atherosclerosis is well established in animal models [9]. In 
particular, VCAM-1 mediates firm adhesion, tethering, 
rolling of monocytes and facilitates their transendothelial 
Fig. 2 Cell phantom preparation. Six samples were prepared. They are the activated cells stimulated by TNF-α of different concentration (1 ng/mL, 
10 and 100 ng/mL). The controls are activated cells with biotinylated IgG antibodies and microbeads as negative control, unactivated cells as nega-
tive control, and streptavidin microbeads
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migration at the developing atheroma [26]. Its expression 
is upregulated on activated endothelium under inflam-
matory conditions, including atherosclerosis [7], trans-
plant rejection [27] and cancer [28]. Davies et  al. [29] 
found VCAM-1 expression in a majority of post-mortem 
human coronary atherosclerotic plaques. Furthermore, 
decreased VCAM-1 expression in experimental athero-
sclerosis appears after treatment with either HMG-CoA 
reductase inhibitors [30] or angiotensin receptor block-
ers [31]. A reduction in atherosclerotic lesion formation 
was found in genetically modified mice with impaired 
VCAM-1 function [26].
VCAM-1 expression is not constitutive of, but does 
appear on endothelial cell surface in atheroprone sites 
even before the onset of visible disease, with persistent 
expression in more advanced lesions [4]. Consistent 
with these previous studies, we confirmed that VCAM-1 
expression was only detected on the activated mAEC 
(Fig. 4), but not on the silent control cells (Fig. 4).
McAteer et al. [4] demonstrated a dose dependent effect 
on the in  vitro binding of anti-VCAM-1 microparticles 
of iron-oxide (MPIO) to TNF-α-stimulated endothelial 
cells. We also observed similar dose-dependent increase 
in VCAM-1 expression, i.e. greater expression on the cells 
activated by higher concentration of TNF-α.
Unlike P-selectin, previous studies reported that 
VCAM-1 had different kinetics of expression on human 
endothelial cells, with a later onset and a more prolonged 
duration of at least 72  h compared to that of P-selectin 
Fig. 3 Immunocytochemistry for P-selectin on activated mAEC by 
different concentrations of TNF-α (0.1, 1, 10, 100 ng/mL) at different 
incubation period (4, 24, 48 h). a Red fluorescence signal for P-selectin 
expression. Blue DAPI staining for cell nuclei. Magnification ×60. b 
The intensity of staining obtained with anti-P-selectin antibody was 
quantified as corrected total cell fluorescence (CTCF) (mean ± SEM). 
Statistical significance is established at P < 0.05 (*P < 0.05, **P < 0.01, 
***P < 0.001) and ns represents not significant
Fig. 4 Immunocytochemistry for VCAM-1 on activated mAEC by 
different concentrations of TNF-α (0.1, 1, 10, 100 ng/mL) at different 
incubation period (4, 24, 48 h). a Red fluorescence signal for VCAM-1 
expression. Blue DAPI staining for cell nuclei. Magnification ×60. b 
The intensity of staining obtained with anti-VCAM-1 antibody was 
quantified as corrected total cell fluorescence (CTCF) (mean ± SEM). 
Statistical significance is established at P < 0.05 (*P < 0.05, **P < 0.01, 
***P < 0.001) and ns represents not significant
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[32]. Our study revealed similar results: greater level of 
VCAM-1 expression was observed with longer incuba-
tion period. The VCAM-1 expression on activated mAEC 
revealed at 4  h after stimulation by TNF-α, increased 
with longer incubation period and sustained a marked 
level of expression at 48 h.
The strict temporal regulation of these inducible 
endothelial adhesion molecules, their critical functions 
in atherosclerosis and their immediate accessibility via 
the circulation provide valuable targets for functional 
molecular imaging and targeted therapeutics. This poten-
tially provides a new biologically based imaging modality 
beyond anatomy to identify the ‘at risk’ group with unsta-
ble plaque disease, affording the opportunity for early 
stroke preventive treatment.
In vitro studies‑MRI of cells
Figure  5 shows that the activated cells stimulated by 
higher concentration of TNF-α produced greater signal 
void and appeared darker in the MRI. The S/N values 
were consistent with these observations of MRI of the 
cell phantoms. The higher concentration of TNF-α used 
to activate the mAEC, the greater level of P-selectin and 
VCAM-1 expression on these cells. Therefore, greater 
amount of streptavidin microbeads were bound to the 
biotinylated anti-P-selectin and anti-VCAM-1 antibod-
ies. Hence, greater signal loss was detected by MRI and 
lower S/N in mAEC activated by higher concentration 
of TNF-α. Therefore, we have successfully demonstrated 
an in vitro model to detect and characterise inflamma-
tion of endothelial cells by immunocytochemistry and 
MRI.
Similar in  vitro studies with MRI of cell phantoms 
have been reported previously by McAteer et  al. [4]. 
VCAM-1 conjugated microparticles of iron-oxide 
(MPIO) bound to TNF-α stimulated endothelial cells, 
but did not bind to unstimulated cells. The number 
of cell-bound VCAM–MPIO increased with increas-
ing dose of TNF-α. MRI of cell phantoms showed 
punctate dark signal areas (hypointensity) represent-
ing VCAM-1–MPIO binding to cells, which increased 
with higher dose of TNF-α. Reynolds et  al. demon-
strated that E-selectin expression on activated vascular 
endothelium could be selectively and directly imaged 
non-invasively with in vivo MR by using anti-E-selectin 
antibody conjugated ultrasmall superparamagnetic iron 
oxide (USPIO) [15].
Present challenges for in vivo molecular MRI
The present challenge for in  vivo molecular imaging is 
to deliver an effective contrast agent in sufficient quan-
tity to the arterial wall in  vivo. For a contrast agent to 
be effective, it must provide high sensitivity and relax-
ivity for detection by MRI. It also needs to be stable 
under physiological conditions. In addition, it has to be 
membrane permeable, non-cytotoxic, functionalisable 
and highly specific. There is a rapid growth in the use 
of iron-oxide particles for detecting vascular inflamma-
tion in  vivo with MRI [15, 33–35]. Tang et  al. [33] and 
Kawahara et  al. [34] utilised the non-specific uptake of 
USPIO and SPIO by macrophages to identify plaque 
inflammation in humans. It has been speculated that this 
contrast medium is phagocytosed by macrophages and 
accumulates in the atherosclerotic lesions. This was an 
indirect method to visualise the plaque by macrophage 
infiltration. A relatively high dose of the agent is neces-
sary to obtain good contrast effect and accumulation 
takes up to 24 h. In contrast, our study is a pilot qualita-
tive study where MRI with antibody-conjugated SPIO is 
Fig. 5 The transaxial view of cell phantom MRI. a T2 sequence. In 
clockwise direction: the microbeads, activated mAEC stimulated by 
TNF-α of different concentrations (100, 10 and 1 ng/mL), activated 
mAEC added with biotinylated IgG antibodies and microbeads and 
unactivated mAEC. b The S/N in streptavidin microbeads, positive 
control, was the smallest amongst all the samples. The activated cells 
stimulated by higher concentration of TNF-α produced a lower S/N. 
By contrast, the negative controls: (1) unactivated mAEC, and (2) acti-
vated mAEC added with biotinylated IgG antibodies and microbeads 
produced high S/N
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used to assess the specific molecular events of vascular 
inflammation. Thus far, we have successfully developed 
an in  vitro model to detect and characterise inflamma-
tion on the endothelial cells by both immunocytochem-
istry and MRI.
Conclusion
We have established a robust in  vitro model of vascu-
lar inflammation using mAEC induced with TNF-α. We 
have successfully detected and characterised the inflam-
mation of endothelial cells by immunocytochemistry and 
MRI, which offers the potential for future translational 
studies to detect vascular inflammation in atherosclero-
sis. The results revealed a temporal expression in P-selec-
tin and VCAM-1. In addition, the results suggested that 
the level of P-selectin and VCAM-1 expression was dose 
dependent on exposure to TNF-α.
This proof-of-concept work may form the basis for 
further translational studies to provide clinicians with a 
novel tool for in vivo assessment of atherosclerosis. This 
will potentially fulfil the current gap to identify vulner-
able patients, to better define cardiovascular risk and to 
guide therapy more rationally, thereby contributing to a 
personalised approach to the management of atheroscle-
rotic disease in the future.
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